SMi’s 5th Annual Conference on Drug Design V
27th & 28th February 2006, Grange Holborn Hotel, London Sponsored by: Chemical Computing Group, Accelrys, Simulations Plus, Coalesix & MicroCal Supported by: HTScreening.net, Combichem.net, Admet.net, Journal of Drug Targeting, Drug Discovery Today, Pharmafocus, Pharmafile, Inpharma.com, DrugResearcher.com and Taylor & Francis
This event will address how both the pharmaceutical and biotechnology industries can identify early failures whilst increasing the number of potential hits quicker and faster with new techniques being made available.
Benefits of Attending:
- Structure-based Drug Design: Hear about all areas of SBDD including structure-based lead generation and optimisation, as well as rational drug design techniques and how and when to use them
- Virtual Screening: Learn the different techniques available, improvements being made in hit-to-lead and the effectiveness of different screening methods. Discover new ways of identifying drugable targets and flaws in current chemotype approaches
- Pharmacognosy: Gain knowledge from industry experts on how to incorporate natural products into drug discovery and design
- Computational Drug Design: Understand the application methods specific to protein-ligand groups and their performance, whilst gaining insight into finding and exploiting local QSAR
- Data Analysis and Library Design: See examples of risk management for productivity and attrition, integration of NMR and identifying and choosing the right leads
- Networking Opportunities: Meet the leaders in the field, make valuable contacts and learn from their experience and expertise
Hear from leading industry experts including:
- Dr Joseph Bolen, Senior Vice President, Discovery, Millennium
- Dr Jeffrey Wiseman, Vice President & Officer, Technology & Informatics, Locus Pharmaceuticals
- Dr Jonathan Mason, Executive Director, Medicinal Informatics Structure & Design, Pfizer
- Dr Alexander Alex, Director, Pfizer
- Dr Michael Hennig, Vice Director, Molecular Structure Research, F. Hoffmann-La Roche
- Dr Philip Jewsbury, Associate Director, Computational Chemistry, AstraZeneca
- Dr Peter Hunt, Research Fellow, Merck, Sharp & Dohme
PLUS A HALF-DAY POST-CONFERENCE EXECUTIVE BRIEFING
NMR Fragment Screening: Techniques & Applications
1st March 2006, Grange Holborn Hotel, London
In association with: CombiNature
To view the programme online visit: http://www.smi-online.co.uk/goto/drugdesignv.asp?emref=T19EL231063506
Offers are also available for group bookings, contact Anthony Bennett on
tel: +44 (0)20 7827 6720 or mailto:abennett@smi-online.co.uk
